GRI Bio, Inc.
GRI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GRI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GRI
GRI Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies targeting natural killer T (NKT) cells for inflammatory, fibrotic, and autoimmune diseases, with lead candidate GRI-0621 in development for idiopathic pulmonary fibrosis (IPF) and other indications.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial for GRI Bio, Inc..
GRI Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies targeting natural killer T (NKT) cells for inflammatory, fibrotic, and autoimmune diseases, with lead candidate GRI-0621 in development for idiopathic pulmonary fibrosis (IPF) and other indications.
- Lead product candidate GRI-0621 is being developed for idiopathic pulmonary fibrosis (IPF) and other inflammatory/fibrotic indications [sec_mda · as of 2026-08-14].
- Cash and cash equivalents were $10.9M as of 2026-06-30, with a net loss of -$1.6M for the period [sec].
- Management believes existing cash will fund operations through the second quarter of 2027, but only for preliminary work toward a Phase 2b trial of GRI-0621 [sec_mda · as of 2026-08-14].
- The company has expressed substantial doubt about its ability to continue as a going concern without additional financing [sec_mda · as of 2026-01-30].
- GRI Bio plans to file an IND in 2026 for GRI-0803, a candidate targeting systemic lupus erythematosus (SLE) [sec_mda · as of 2026-01-30].
What works
- GRI Bio has a focused pipeline targeting NKT cell biology, with GRI-0621 in clinical development for IPF and GRI-0803 advancing toward an IND for SLE [sec_mda · as of 2026-01-30].
- The company has sufficient cash runway through Q2 2027 for preliminary work on GRI-0621, providing a near-term operational buffer [sec_mda · as of 2026-08-14].
- GRI Bio intends to pursue business development opportunities to expand its product portfolio and supporting technologies [sec_mda · as of 2026-01-30].
What to weigh
- Management has expressed substantial doubt about the company's ability to continue as a going concern, and auditors have raised similar concerns [sec_mda · as of 2026-01-30].
- The company will require substantial additional capital to complete a Phase 2b trial of GRI-0621, and there is no assurance such financing will be available [sec_mda · as of 2026-08-14].
- GRI Bio has a history of losses and expects to continue incurring significant expenses, with no approved products or revenue from product sales [sec · filed 2026-01-30].
- The company's business is highly dependent on the success of GRI-0621, and clinical development involves a lengthy, complex, and expensive process with uncertain outcomes [sec_mda · as of 2025-03-14].
From the filings
Quoted directly from source documents.
Cash runway through Q2 2027 is only for preliminary work on GRI-0621, not for completing a Phase 2b trial.
“Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to fund out currently planned operating expenses and capital expenditure requirements through the second quarter of 2027. However, this estimate assumes that we only continue the preliminary work towards the initiation of additional clinical studies of GRI-0621; we would not be able to complete the additional clinical studies for GRI-0621, which will require substantial additional capital or resources.”
SEC MD&A · August 14, 2026
Management has expressed substantial doubt about going concern.
“Our management has expressed substantial doubt about our ability to continue as a going concern”
SEC MD&A · January 30, 2026
GRI-0803 IND expected in 2026 for SLE.
“Subject to IND clearance, we intend to evaluate GRI-0803 in a Phase 1a and 1b trial in healthy volunteers. We expect to file an IND with respect to this trial in 2026.”
SEC MD&A · January 30, 2026
Business is highly dependent on GRI-0621.
“Our business is highly dependent on the success of our lead product candidate, GRI-0621, and any other product candidates that we may advance into clinical development.”
SEC MD&A · March 14, 2025
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Management has expressed substantial doubt about the company's ability to continue as a going concern [sec_mda · as of 2026-01-30].
- Need for substantial additional capital — Completing a Phase 2b trial of GRI-0621 requires substantial additional capital, with no assurance of financing [sec_mda · as of 2026-08-14].
- Dependence on lead candidate — The business is highly dependent on the success of GRI-0621, which is still in early clinical development [sec_mda · as of 2025-03-14].
- History of losses and no revenue — The company has a history of losses and expects to continue incurring significant expenses with no approved products [sec · filed 2026-01-30].
What to watch
- Ability to raise additional capital to fund the Phase 2b trial of GRI-0621 and ongoing operations [sec_mda · as of 2026-08-14].
- IND filing and initiation of Phase 1a/1b trial for GRI-0803 in SLE, expected in 2026 [sec_mda · as of 2026-01-30].
- Progress of preliminary work toward the Phase 2b trial of GRI-0621 and any clinical data updates [sec_mda · as of 2026-08-14].
- Potential business development or partnership opportunities to expand the pipeline [sec_mda · as of 2026-01-30].
Sources: SEC filings · SEC MD&A · Generated August 21, 2026 · How we verify sources →
Run GRI Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available GRI Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
23.0 months
D/E 0.11 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$42K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 18,438 | $42K |
| blackrock, inc. | 7 | $16 |
| danske bank a/s | 2 | $5 |
Short Interest
as of Apr 30, 2026- % of float
- 9.3%
- Days to cover
- 0.9
- Shares short
- 134,378
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GRI short interestFrequently asked questions
What is the AI investment thesis for GRI Bio, Inc.?
GRI Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies targeting natural killer T (NKT) cells for inflammatory, fibrotic, and autoimmune diseases, with lead candidate GRI-0621 in development for idiopathic pulmonary fibrosis (IPF) and other indications.
What is GRI Bio, Inc.'s lead drug candidate?
GRI Bio, Inc.'s most advanced tracked candidate is gri-0621 (Phase 2) for Idiopathic pulmonary fibrosis (IPF).
Who is the CEO of GRI Bio, Inc.?
Dr. W. Marc Hertz Ph.D. is the chief executive officer of GRI Bio, Inc. (GRI).
Where is GRI Bio, Inc. headquartered?
GRI Bio, Inc. (GRI) is headquartered in La Jolla, CA, United States.
What therapeutic areas does GRI Bio, Inc. focus on?
GRI Bio, Inc. develops therapies across Immunology, Respiratory, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.